Autopsy report · NCT07693374
Chinese Medicinal Component Relieves CIPN and Mitochondria Function
Cause of deathSlow enrollment, also safety
“Initial prep showed that formulation, QC, and cost for high-dose paeonol/Cortex Moutan exceeded the budget. Also, recruiting patients with chemotherapy-induced peripheral neuropathy was limited. To ensure safety, enrollment did not officially launch.”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Na
- Sponsor
- Taiwan Municipal An-Nan Hospital-China Medical University
- Sponsor type
- University, hospital or other
- Conditions
- Breast Cancer; Chemotherapy-induced Peripheral Neuropathy (CIPN)
- Interventions
- Moutan cortex; sham moutan cortex
- Participants
- 0
- Sites
- 1
- Countries
- Taiwan
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.